AstraZeneca to Divest European Rights of Crestor (rosuvastatin) to Grünenthal for ~$350M


  • Grünenthal to acquire EU rights (Ex- Spain and the UK) of Crestor & its associated brands for ~$350M and will take over bulk production and packaging by 2025. The deal is expected to be closed in Q1’21
  • The payments will be made in two tranches: $320M will be paid upon transaction closing and $30M as additional milestones
  • Crestor is a statin, a lipid-lowering agent used to treat blood-lipid disorders & to prevent CV events, such as heart attacks & strokes, and is approved as a lipid-regulating medicine in 100+ countries

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Wikipedia

The post AstraZeneca to Divest European Rights of Crestor (rosuvastatin) to Grünenthal for ~0M first appeared on PharmaShots.

The Dawn of a European Health Data Space – Challenges

The European data strategy aims to construct common data spaces for all, create a single EU market for data, and catalyze a dynamic data economy. In a previous post, we briefly described the essence of the envisioned heath data space and pointed at opportunities and possible starting points to transform this vision into reality.

However, several questions have also emerged in exchanges with
thought leaders and collaborators. Borne from gray areas around data, systems
and mechanisms for common use, these questions serve as food for thought
to structure an open, cross-sector discussion.

What data

We need to talk honestly about data quality and data bias. In our
experience with AI, efforts to make data reliable, transparent and reusable go
a long way in catalyzing new, machine-based data exploration. Part of that
effort is to define the amount and type of bias permissible in data for a
particular purpose because there are no data without bias.

Which system

Vast amounts of data on biology, chemistry and health need to be
machine-readable on a massive scale. Manual curation is not an option, but in a
framework that spans from big data in populations to patient-centric care –
where data are personal and private by definition – how do we verify the
fidelity of automated processing and build trust in the system?

Where to guide

Central guidance is essential for unified empowerment, but
individuals should participate in a common data space because they understand
the benefits and not just because there are safeguards against risks. Robust
but flexible guidance can address seemingly insurmountable differences among
sectors in the way data are generated and valued, while ensuring that abuses
are not rewarded. We need to understand the interests and objectives of all
parties. Only so can these spaces be truly inclusionary.

It is time for a dialogue – time to openly define the needs,
interests, objectives and differences of participants in an EU health data
space. We want to hear your thoughts; not only about the nature of these data
spaces but also about the forum in which clinical researchers and data
scientists can access unified research, literature and clinical data in one
secure environment. To join the discussion, please email my colleague Xuanyan
Xu at [email protected].

The Dawn of a European Health Data Space – Opportunities

At the beginning of 2020, the European Commission introduced a “European strategy for data.” The document proposes to bolster and advance the data economy in Europe with a view towards capturing “the benefits of better use of data, including greater productivity and competitive markets, but also improvements in health and well-being, environment, transparent governance and convenient public services.”

Salient was the announcement’s inclusionary language, that “data should be available to all – whether public or private, big or small, start-up or giant.” Also revealing was its concurrent release with a White Paper on artificial intelligence (AI). The EC recognizes that diverse data come from across sectors and are intimately entwined with AI – one cannot exist without the other. Just as abundant, high-quality data are an absolute requisite for meaningful AI, the potential of AI drives today’s value and use of big data.

One pillar of the EU data strategy is the establishment of common
European data spaces in domains of public interest. Among those is health data,
with two broad action items carefully embedded in the context of GDPR:

  • Create legislature to strengthen citizen access to and portability of their own health data, as well as a code of conduct for processing those data in the healthcare sector.
  • Deploy infrastructure that supports interoperability of electronic health records, federated data repositories, genomic information, medical images, laboratory results, prescriptions and other documentation to not only ease healthcare administration, but also foster research and innovation toward discovering, regulating and legislating effective therapies that prevent, diagnose and treat diseases.

Altogether, this as an opportunity. The EC envisions constructing an ecosystem of experimentation, creativity and differentiation to produce new businesses (think: BenevolentAI) and data-based tools that, for example, yield novel antibiotics, predict synergistic combination therapies for cancer, or discover drug candidates to repurpose for rare diseases.

Recently, we’ve developed and nurtured open data aggregations as our contribution to the global response against SARS-CoV-2. The COVID-19 Mendeley Data and Coronavirus Research Hub may offer ideas on how to institutionalize data spaces. We are looking for partners to develop this concept and start a dialogue from which an EU data space can evolve. Please contact my colleague Xuanyan Xu at [email protected] if you are interested in participating.